Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.
Ma X, Zou F, Yu F, Li R, Yuan Y, Zhang Y, Zhang X, Deng J, Chen T, Song Z, Qiao Y, Zhan Y, Liu J, Zhang J, Zhang X, Peng Z, Li Y, Lin Y, Liang L, Wang G, Chen Y, Chen Q, Pan T, He X, Zhang H. Ma X, et al. Among authors: deng j. Immunity. 2020 Dec 15;53(6):1315-1330.e9. doi: 10.1016/j.immuni.2020.11.015. Epub 2020 Nov 25. Immunity. 2020. PMID: 33275896 Free PMC article.
Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques.
Li R, Ma X, Deng J, Chen Q, Liu W, Peng Z, Qiao Y, Lin Y, He X, Zhang H. Li R, et al. Among authors: deng j. Cell Mol Immunol. 2021 Apr;18(4):1058-1060. doi: 10.1038/s41423-021-00641-8. Epub 2021 Feb 12. Cell Mol Immunol. 2021. PMID: 33580167 Free PMC article. No abstract available.
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2.
Yuan Y, Zhang X, Chen R, Li Y, Wu B, Li R, Zou F, Ma X, Wang X, Chen Q, Deng J, Zhang Y, Chen T, Lin Y, Yan S, Zhang X, Li C, Bu X, Peng Y, Ke C, Deng K, Pan T, He X, Zhang Y, Zhang H. Yuan Y, et al. Among authors: deng k, deng j. Cell Rep. 2022 Jan 18;38(3):110256. doi: 10.1016/j.celrep.2021.110256. Epub 2021 Dec 23. Cell Rep. 2022. PMID: 34990583 Free PMC article.
Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants.
Chen R, Zhang X, Yuan Y, Deng X, Wu B, Xi Z, Wang G, Lin Y, Li R, Wang X, Zou F, Liang L, Yan H, Liang C, Li Y, Wu S, Deng J, Zhou M, Zhang X, Li C, Bu X, Peng Y, Ke C, Deng K, He X, Zhang Y, Zhang Z, Pan T, Zhang H. Chen R, et al. Among authors: deng k, deng j, deng x. Adv Sci (Weinh). 2022 Apr;9(11):e2105378. doi: 10.1002/advs.202105378. Epub 2022 Feb 10. Adv Sci (Weinh). 2022. PMID: 35142444 Free PMC article.
A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross-Protection Activity against Multiple SARS-CoV-2 Sublineages.
Zhang X, Wu S, Liu J, Chen R, Zhang Y, Lin Y, Xi Z, Deng J, Pu Z, Liang C, Feng J, Li R, Lin K, Zhou M, Liu Y, Zhang X, Liu B, Zhang Y, He X, Zhang H. Zhang X, et al. Among authors: deng j. Adv Sci (Weinh). 2023 Sep;10(27):e2301034. doi: 10.1002/advs.202301034. Epub 2023 Aug 1. Adv Sci (Weinh). 2023. PMID: 37526323 Free PMC article.
The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis.
He X, Zhang X, Wu B, Deng J, Zhang Y, Zhu A, Yuan Y, Lin Y, Chen A, Feng J, Wang X, Wu S, Liu Y, Liu J, Wang Y, Li R, Liang C, Yuan Q, Liang Y, Fang Q, Xi Z, Li W, Liang L, Zhang Z, Tang H, Peng Y, Ke C, Ma X, Cai W, Pan T, Liu B, Deng K, Chen J, Zhao J, Wei X, Chen R, Zhang Y, Zhang H. He X, et al. Among authors: deng k, deng j. Nat Immunol. 2024 Apr;25(4):622-632. doi: 10.1038/s41590-024-01776-2. Epub 2024 Mar 7. Nat Immunol. 2024. PMID: 38454157
10,589 results
You have reached the last available page of results. Please see the User Guide for more information.